Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Luteinizing Hormone Test Market size is poised to grow at substantial growth rate during the forecast period i.e., between 2025-2037.
The increasing infertility rate globally, along with the growing investment in the innovation of technologically improved products are expected to fuel the development of the market. The growth of the market can also be attributed to factors, such as, the increasing awareness among the population towards gynaecological problems and the rising middle-class population in the emerging economies on a global level. According to the data collected from the World Health Organization (WHO), in 2020, approximately 48 million couples, and 186 million individuals across the globe live with infertility. Such increasing number of infertility rate has rapidly increased the requirement for luteinizing hormone test in the market. Moreover, the growing incidence rate of prostate cancer is another major factor coupled with raised chances of living of a person when treated with luteinizing hormone releasing hormone (LHRH) agonist therapy combined with surgery is expected to boost the luteinizing hormone test market growth. Furthermore, the propelling demand for ovulation and fertility monitors in emerging economies is expected to develop remarkably in the upcoming years on account of the rising prevalence of PCOS, increasing infertility rates, obesity, growing fertility education, and easy availability of fertility monitors through online platforms, pharmacies, and offline stores, drugstores.
Luteinizing Hormone Test Sector: Growth Drivers and Challenges
Growth Drivers
- Rising Cases of Infertility
- Increasing in the Incidence of Male Hypogonadism
Challenges
- Strict Regulations on Test Quality by FDA
- Lack of Accuracy & Specificity
Luteinizing Hormone Test Market: Key Insights
|
2023 |
|
|
Forecast Year |
2024–2036 |
|
Regional Scope |
|
Luteinizing Hormone Test Segmentation
The luteinizing hormone test market is segmented by disease indication into irregular menstrual cycle, infertility, PCOS, pituitary disorder, and others, out of which, the infertility segment is anticipate to garner a notable market share over the forecast period, owing to the increasing concerns regarding infertility among couples. According a report by the Centres for Disease Control and Prevention (CDC), 8.8% women between 15 to 49 years of age experience infertility in the U.S., as of 2017. Based on distribution channel, the market is segmented into hospitals, clinics, diagnostic centres, fertility centres, and others. Out of these, the fertility centres segment is estimated to hold the largest share in the luteinizing hormone test market throughout the forecast period, on the back of growing concern and awareness for infertility among the couples and individuals across the developing and developed countries.
Our in-depth analysis of the global market includes the following segments:
|
Disease Indication |
|
|
End-User |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportLuteinizing Hormone Test Industry - Regional Synopsis
Asia Pacific industry is likely to account for largest revenue share by 2037, owing to growing population, increasing awareness regarding infertility among the individuals in the region., owing to growing population, increasing awareness regarding infertility among the individuals in the region.The market in North America is anticipated to garner the largest share in terms of revenue, owing to the increasing incidence of infertility among the women aged between 15-44 years in the region. According to other report by the CDC, annually approximately 6.1 million women, that is 10% of the women in the U.S., face difficulty to conceive or staying pregnant. Such increasing issues during the reproductive age among the individuals and couples is further expected to drive the demand for luteinizing hormone test in the North American countries.
Companies Dominating the Luteinizing Hormone Test Landscape
- Merck & Co.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Cigna Corporation
- Lee BioSolutions, Inc.
- Proov Inc.
- Swiss Precision Diagnostics GmbH
- Abbott Laboratories
- Quidel Corporation
- Geratherm Medical AG
- bioMérieux SA
- CIGA Healthcare Ltd
In the News
- March 2020: Proov Inc., announced the approval of their new range of at home ovulation testing kit by the FDA. It claims to provide 99% correct results in 5 minutes.
Author Credits: Radhika Pawar
- Report ID: 3138
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT
